TerminatedNot Applicable

Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease

Stopped: Low recruitment

United States14 participantsStarted 2015-08-26

Plain-language summary

This study assesses if using the medication desmopressin will decrease nightime bedwetting in children with sickle cell disease.

Age range8 Years – 21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Patients with Hemoglobin SS, SC, SB0thal or SB+thal
✓. Patients with at least two episodes of primary nocturnal enuresis per week or four episodes over the two weeks prior to enrollment.
✓. Patients with secondary enuresis who have been evaluated and cleared by a pediatric urologist as not having other etiologies of enuresis (e.g. overactive detrusor activity, a genitourinary anatomic abnormality)

✕. Patients with developmental delay or neurologic dysfunction secondary to stroke.
✕. Patients with hypertension or underlying renal disease.
✕. Patients with genitourinary anatomic abnormalities. Any prior renal ultrasound showing normal genitourinary anatomy is sufficient to clear a patient for the study.
✕. Patients with daytime urinary incontinence
✕. Patients with glucosuria on urinalysis.
✕. Patients with secondary nocturnal enuresis who have not been evaluated by a pediatric urologist to rule out other etiologies of enuresis.
✕. Patients who are pregnant.
✕. Patients receiving another medicine for nocturnal enuresis (e.g. imipramine).

Reduction in Bedwetting episodes

Timeframe: Baseline and 4 weeks

NCT IDNCT02636387

SponsorMontefiore Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-10-27